Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zecdarasib + SNV1521
- Development stage
- Unknown
- Lead developer
- Incyte
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
INCB161734 + SNV1521 is an investigational combination of two oral small-molecule targeted anticancer agents: zecdarasib (INCB161734), a selective non-covalent ON/OFF KRAS G12D inhibitor, and SNV1521, a selective, brain-penetrant PARP1 inhibitor. Developed through a clinical trial collaboration between Incyte and Synnovation, the combination is being evaluated in a Phase 1b clinical trial for the treatment of patients with advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). The therapeutic rationale is to synergistically target KRAS G12D-driven oncogenic signaling while simultaneously inhibiting PARP1-mediated DNA damage repair, thereby enhancing genomic instability and tumor cell apoptosis in KRAS G12D-mutated pancreatic cancers.
- Other names
- INCB161734 + SNV-1521INCB-161734 + SNV-1521INCB-161734 + SNV1521SNV-1521 + zecdarasibSNV1521 + zecdarasibzecdarasib + SNV-1521zecdarasib + SNV1521
02
Targets
KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)PARP1 (Poly (adp-ribose) polymerase 1)
Beyond the preview
Go deeper on zecdarasib + SNV1521.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zecdarasib + SNV1521.